FOLH1 and neuroendocrine neoplasm: Only one feasibility study with application of [161Tb]Tb-DOTATOC in 2 patients with neuroendocrine neoplasms and two case reports of PSMA-RLT with [161Tb]Tb-PSMA-617 have been published yet, all showing promising results 33-35.